# Cancer Partnerships Working Group

Working Group Leadership: Ratain and McLeod

Working Group Membership: David Flockhart, Deanna Kroetz, Dick Weinshilboum, Todd Skaar, Jim Ingle, Mary Relling, Federico Innocenti, Kathy Giacomini, Nancy Cox, Mike Province, Liewei Wang, Dan Hayes

U Chicago, UNC-Chapel Hill, Indiana U, UCSF, Mayo, St Jude, WashU, U Michigan



## Working Group Charge

 Develop a process to optimize the conduct of pharmacogenetic genomewide association studies in collaboration with publicly funded cancer trials groups



#### **Tasks**

- 1. Design one or more genome-wide pharmacogenetic studies in collaboration with the NCI Cooperative Groups
- 2. Develop a plan for whole genome typing for specimens obtained from the NCI Cooperative Groups
- 3. Initiate one or more genome-wide pharmacogenetic studies in collaboration with the NCI Cooperative Groups
- Execute one or more master agreements with the Cooperative Groups
- 5. Identify additional NCI Cooperative Groups for which there may be opportunities for collaboration




## Cancer Partnerships Working Group

- 11/06: identification of Riken Institute (Yusuke Nakamura, MD, PhD) as potential partner
- 1/07: preliminary commitment by Dr. Nakamura to collaborate
- 3/07: meeting with CALGB regarding study of bevacizumab and gemcitabine toxicity (phase III study in pancreatic cancer)
- 4/07: meeting with COG regarding study of predictors of osteonecrosis in children
- 4/07: meeting with Dr. Nakamura
- 6/07: CALGB database completed
- 7/07: CALGB protocol amendment
- 9/07: CTEP approval
- 11/07: RIKEN IRB approval
- 12/07-1/08: SNP scan
- 2/08: Visit to Japan, resulting in commitment for ~6 additional genome scans
- 2/08: Data analysis



XX 08: Publication submission







Director Yusuke Nakamura (M.D., Ph.D.)

**Advisory Council** 

Research Group for Genotyping Group Director: Michiaki Kubo (M.D., Ph.D.)

Laboratory for Genotyping
Laboratory Head: Michiaki Kubo (M.D., Ph.D.)

Research Group for Medical Informatics Group Director: Naoyuki Kamatani (M.D., Ph.D.)

Laboratory for Medical Informatics Laboratory Head: Tatsuhiko Tsunoda (Ph.D.)

Laboratory for Statistical Analysis Laboratory Head : Naoyuki Kamatani (M.D., Ph.D.)

Research Group for Disease-caousing Mechanism Group Director: Toshihiro Tanaka (M.D., Ph.D.)

Laboratory for Cardiovascular Diseases
Laboratory Head: Toshihiro Tanaka (M.D., Ph.D.)

Laboratory for Rheumatic Diseases Laboratory Head: Kazuhiko Yamamoto (M.D., Ph.D.)

Laboratory for Bone and Joint Diseases Laboratory Head : Shiro Ikegawa (M.D., Ph.D.)

Laboratory for Genetics of Allergic Diseases Laboratory Head : Mayumi Tamari (M.D., Ph.D.)

Laboratory for Diabetic Nephropathy Laboratory Head: Shiro Maeda (M.D., Ph.D.)

Laboratory for Obesity Laboratory Head : Kikuko Hotta (M.D., Ph.D.)

Laboratory for Liver Diseases Laboratory Head : Kazuaki Chayama (M.D., Ph.D.)

Laboratory for Gastrointestinal Diseases Laboratory Head: Akira Hata (M.D., Ph.D.)

Laboratory for Pharmacogenetics Laboratory Head: Taisei Mushiroda (M.D., Ph.D.)



### Cancer Partnerships Working Group

- 11/06: identification of Riken Institute (Yusuke Nakamura, MD, PhD) as potential partner
- 1/07: preliminary commitment by Dr. Nakamura to collaborate
- 3/07: meeting with CALGB regarding study of bevacizumab and gemcitabine toxicity (phase III study in pancreatic cancer)
- 4/07: meeting with COG regarding study of predictors of osteonecrosis in children
- 4/07: meeting with Dr. Nakamura
- 6/07: CALGB database completed
- 7/07: CALGB protocol amendment
- 9/07: CTEP approval
- 11/07: RIKEN IRB approval
- 12/07-1/08: SNP scan
- 2/08: Visit to Japan, resulting in commitment for ~6 additional genome scans
- 2/08: Data analysis



XX 08: Publication submission